Skip to main content
. 2022;22(3):305–315.

Table 1.

Patients’ characteristics and histomorphometric dynamic indices of bone formation.

Patients with T2DM (n=26)
Αge (yrs) 41.5 [38.0; 45.3]
Duration of T2DM (yrs) 8.0 [6.0; 13.3]
Body mass index 32.4 [28.9; 34.5]
Chronic complications (nb. of pat.) 9
Vertebral fractures1 (nb. of pat.) 3
HbA1c (%) 7.6 [6.2; 9.6]
 HbA1c <7% / >7% (nb. of pat.) 10 / 16
Medication
 Metformin (nb. of pat.) 23
 SGLT2 (nb. of pat.) 3
 Insulin (nb. of pat.) 13
Serum parameters
 FBG (mg/dL) 148.0 [103.8; 235.8]
 Calcium (mg/dL) 9.2 [8.9; 9.5]
 Phosphate 3.6 [3.3; 4.0]
 Intact PTH (pg/dL) 44.9 [36.6; 60.8]
 Pentosidine (pmol/mL) 3596 [1501; 4541]
Histomorphometric parameters
 BV/TV (%) 29.0 [23.0; 31.0]2
 MS/BS (%) 1.4 [0.5; 4.0]3
 MAR (µm/day) 0.61 [0.30; 0.71]3
 BFR/BS (µm3⋅µm-2⋅d-1) 0.007 [0.002; 0.023]3

Data are median (25th, 75th percentiles).

1

diagnosis was based on lateral X-ray of the thoracic and lumbar spine (from T4 to L4) by the method described by Genant[44].

2

BV/TV of both subgroups with good (HbA1c<7%) or poor glycemic control (HbA1c>7%) are significantly higher compared to BV/TV of control group from previous publication[20].

3

No comparison of dynamic indices with control group available from previous publication[20], however dynamic indices do not differ to premenopausal OLS-control group of the current work (all p>0.05).

Abbreviations: HbA1c = glycated; hemoglobin; SGLT2 = type 2 sodium-glucose cotransporter inhibitors; FBG = fasting blood glucose; PTH = parathyroid hormone